和誉-B(02256):和誉医药以口头报告形式展示其口服PD-L1抑制剂 ABSK043的最新1期研究结果

智通财经
06 Dec 2024

智通财经APP讯,和誉-B(02256)发布公告,该公司的附属公司上海和誉生物医药科技有限公司(和誉医药)宣布,其已在于新加坡举办的2024年欧洲肿瘤内科学会亚洲年会(ESMO Asia 2024)上以口头报告形式展示其自主研发的口服PD-L1 抑制剂ABSK043治疗晚期实体瘤患者的最新1期研究结果。

研究结果表明,在600mg-1000mg BID剂量组,ABSK043单药具有良好的安全性和抗肿瘤活性。在PD-L1高表达的非小细胞肺癌(NSCLC)患者中,即使患者存在EGFR或KRAS突变,并曾接受过系统性治疗,也能观察到更显著的疗效。这些发现将持续支持ABSK043在EGFR突变肺癌和各种其他实体瘤中的进一步研究。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10